Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40RNN | ISIN: US13463J1016 | Ticker-Symbol:
NASDAQ
06.06.25 | 21:51
1,910 US-Dollar
+2,69 % +0,050
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CAMP4 THERAPEUTICS CORP Chart 1 Jahr
5-Tage-Chart
CAMP4 THERAPEUTICS CORP 5-Tage-Chart

Aktuelle News zur CAMP4 THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.Wedbush bewertet CAMP4-Aktie mit "Outperform" und setzt Kursziel bei 8 US-Dollar1
16.05.CAMP4 Therapeutics: CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders ...1
13.05.Camp4 Therapeutics Corp - 10-Q, Quarterly Report1
CAMP4 THERAPEUTICS Aktie jetzt für 0€ handeln
13.05.Camp4 Therapeutics Corp - 8-K, Current Report1
13.05.CAMP4 Therapeutics: CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights46Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected...
► Artikel lesen
02.05.Pre-market Movers: Classover Holdings, Block, Inc., Advantage Solutions, Ardelyx, CAMP4 Therapeutics816CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Classover Holdings, Inc. (KIDZ) is up over 65% at...
► Artikel lesen
28.04.CAMP4 Therapeutics: CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting1
27.03.Camp4 Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans1
27.03.Camp4 Therapeutics Corp - 10-K, Annual Report1
27.03.Camp4 Therapeutics Corp - 8-K, Current Report1
27.03.CAMP4 Therapeutics: CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update118- Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic...
► Artikel lesen
18.03.CAMP4 Therapeutics: CAMP4 Appoints Multiple Industry Veterans to its Board of Directors1
18.03.Camp4 Therapeutics Corp - 8-K, Current Report1
04.03.CAMP4 Therapeutics Corporation (CAMP): Among Penny Stocks with Insider Buying in 20251
07.01.CAMP4 Therapeutics: CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones182Data from Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 for the treatment of urea cycle disorders (UCDs) demonstrates favorable safety resultsCompleted dosing in the first two...
► Artikel lesen
07.01.Camp4 Therapeutics Corp - 8-K, Current Report-
21.11.24CAMP4 Therapeutics: CAMP4 Reports Third Quarter 2024 Financial Results192- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated...
► Artikel lesen
11.10.24CAMP4 Therapeutics: CAMP4 Announces Pricing of Initial Public Offering206CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1